Across TCGA pan-cancer cohorts, LRRFIP2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated LRRFIP2 data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher LRRFIP2 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated LRRFIP2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
UCEC, DLBC, and SARC are the cancer types where LRRFIP2 Mutation most reproducibly stratifies survival.